When will ozanimod be launched in China?

Ozamod (ozanimod)The original drug was approved by the State Food and Drug Administration on January 31, 2023 and was launched in the country. It is named Ozamod Hydrochloride Capsules and the trade name is Hot Persia. The domestically approved indications include patients with clinically isolated syndrome, relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis. The original Ozamod drug sold overseas is developed and produced by Bristol-Myers Squibb (BMS).

Multiple sclerosis(MS) is a chronic demyelinating and neurodegenerative disease of the central nervous system (CNS) that mainly affects young people, with relapsing-remitting MS (RRMS) being the most common. Ozamod's approval was supported by two Phase 3 studies that demonstrated that it significantly reduced disease recurrence and the number of MRI lesions, reduced brain volume loss, and improved cognitive function. Between 40% and 70% of people with MS experience cognitive impairment, which may occur in the early stages of the disease, before the onset of motor symptoms. OzamodAs a new oral sphingosine1-phosphate receptor modulator, it selectively binds to S1P1 and S1P5 receptors with high affinity, minimizing safety issues caused by S1P3 receptor activation.

Since the original drug Ozamod has been on the market for a short time in China, it has not been included in the medical insurance. The specific price is not yet clear, and domestic purchase channels are difficult. The price of Ozamod original drug specifications0.92*28 capsules per box listed overseas may be around 19,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There is currently no generic version of Ozamod produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.